@article{c810f280d33c44c99153b475303300b0,
title = "IgE binding to linear epitopes of Ara h 2 in peanut allergic preschool children undergoing oral Immunotherapy",
abstract = "Background: For patients with peanut allergy, there are currently no methods to predict who will develop sustained unresponsiveness (SU) after oral immunotherapy (OIT). Objective: Assess IgE binding to peanut (PN), Ara h 2, and specific linear epitopes of Ara h 2 as predictors of the important clinical parameters: eliciting dose threshold and attainment of SU following OIT. Methods: Samples and clinical data were collected from children undergoing OIT. PN- and Ara h 2-sIgE were quantified by ImmunoCAP{\textregistered}. IgE binding to linear peptides of Ara h 2 and Ara h 6 was measured with peptide microarrays. Results: Values of PN-sIgE correlated with eliciting dose (P =.001) and with a higher likelihood of achieving SU (P <.0001), but these relationships were lost at higher values for PN-sIgE (≥14 kIU for eliciting dose and ≥35 kIU/L for SU). In subjects with PN-sIgE ≥ 14 kIU/L, binding of IgE to epitopes 5 and 6 of Ara h 2 was associated with a lower eliciting dose at baseline challenge (P <.001; Pc <.02). In subjects with PN-sIgE ≥ 35 kIU/L, a combined model of IgE binding to epitopes 1, 5 and 6 with PN-sIgE was highly predictive of attainment of SU (AUC of 0.86; P =.0067). Conclusion: In young patients with peanut allergy, measurement of PN-sIgE and IgE binding to specific linear epitopes of Ara h 2 in baseline samples may allow stratification of patients regarding sensitivity to challenge and outcome of OIT.",
keywords = "IgE, allergens, food allergy, immunotherapy, oral immunotherapy, peanut allergy, tolerance induction",
author = "Dreskin, {Stephen C.} and Matthew Germinaro and Dominik Reinhold and Xueni Chen and Vickery, {Brian P.} and Michael Kulis and Burks, {A. Wesley} and Negi, {Surendra S.} and Werner Braun and Chambliss, {Jeffery M.} and Spodra Eglite and McNulty, {Caitlin M.G.}",
note = "Funding Information: This work was supported by an R01‐AI099029 (SCD), NIH NIAID K23 AI099083 (BPV), NIH NIAID R01 AI068074 (AWB), NIH NIAID R21 AI 109090 (WB), and from divisional funds. Also, this work was supported by a grant from the National Center for Advancing Translational Sciences (NCATS) of the NH to the Colorado Clinical and Translational Sciences Institute (CCTSI), UL1TR002535. Contents are the authors{\textquoteright} sole responsibility and do not necessarily represent official NIH views. Funding Information: SCD, XC, BPV, MK, AWB, and WB have received grant support from the National Institutes of Health. BPV is a consultant to Aimmune Therapeutics. MG is an employee of Janssen Pharmaceuticals. AWB has received research grants from Food Allergy Research and Education (FARE), National Institutes of Health, and Wallace Research Foundation. Dr Burks is a consultant on the advisory board for the following: Aimmune (Advisory Panel); Astellas; Biomerica, Inc; Evelo/Epiva Biosciences; GLG Research; Insys Therapeutics; PPD Development; Sanofi US Services; UKKO; and Valeant Pharma North America (consultant). Dr Burks reports ownership interest in Allertein (minority stockholder). DR, SSN, JC, SE, and CMGM have no relevant conflicts of interest. Publisher Copyright: {\textcopyright} 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.",
year = "2019",
month = dec,
day = "1",
doi = "10.1111/pai.13117",
language = "English (US)",
volume = "30",
pages = "817--823",
journal = "Pediatric Allergy and Immunology",
issn = "0905-6157",
publisher = "Blackwell Munksgaard",
number = "8",
}